JP2015505669A - ナチュラルキラー／ｔ細胞リンパ腫（ｎｋｔｃｌ）の感受性予測、診断および治療 - Google Patents

ナチュラルキラー／ｔ細胞リンパ腫（ｎｋｔｃｌ）の感受性予測、診断および治療 Download PDF

Info

Publication number
JP2015505669A
JP2015505669A JP2014543455A JP2014543455A JP2015505669A JP 2015505669 A JP2015505669 A JP 2015505669A JP 2014543455 A JP2014543455 A JP 2014543455A JP 2014543455 A JP2014543455 A JP 2014543455A JP 2015505669 A JP2015505669 A JP 2015505669A
Authority
JP
Japan
Prior art keywords
nktcl
jak3
jak inhibitor
jak
jak1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014543455A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015505669A5 (cg-RX-API-DMAC7.html
Inventor
ビン ティーン テ
ビン ティーン テ
ソン タイ リン
ソン タイ リン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Singapore Health Services Pte Ltd
Original Assignee
Singapore Health Services Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singapore Health Services Pte Ltd filed Critical Singapore Health Services Pte Ltd
Publication of JP2015505669A publication Critical patent/JP2015505669A/ja
Publication of JP2015505669A5 publication Critical patent/JP2015505669A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G01N33/57505—
    • G01N33/57557—
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
JP2014543455A 2011-11-25 2012-11-26 ナチュラルキラー／ｔ細胞リンパ腫（ｎｋｔｃｌ）の感受性予測、診断および治療 Pending JP2015505669A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG2011088002 2011-11-25
SG201108800-2 2011-11-25
PCT/SG2012/000444 WO2013077814A2 (en) 2011-11-25 2012-11-26 Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy

Publications (2)

Publication Number Publication Date
JP2015505669A true JP2015505669A (ja) 2015-02-26
JP2015505669A5 JP2015505669A5 (cg-RX-API-DMAC7.html) 2016-01-21

Family

ID=54257023

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014543455A Pending JP2015505669A (ja) 2011-11-25 2012-11-26 ナチュラルキラー／ｔ細胞リンパ腫（ｎｋｔｃｌ）の感受性予測、診断および治療

Country Status (6)

Country Link
US (2) US20150292022A1 (cg-RX-API-DMAC7.html)
EP (1) EP2782562B1 (cg-RX-API-DMAC7.html)
JP (1) JP2015505669A (cg-RX-API-DMAC7.html)
CN (1) CN104220051B (cg-RX-API-DMAC7.html)
SG (2) SG11201402611WA (cg-RX-API-DMAC7.html)
WO (1) WO2013077814A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020536111A (ja) * 2017-10-06 2020-12-10 シンガポール ヘルス サービシーズ ピーティーイー リミテッド リンパ腫を処置する方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6416508B2 (ja) * 2014-06-05 2018-10-31 公益財団法人がん研究会 Ｎｋ／ｔ細胞リンパ腫の検査方法
AU2017371514B2 (en) * 2016-12-09 2022-12-22 Onk Therapeutics Limited Improved NK-based cell therapy
CN108841869B (zh) * 2018-05-31 2022-05-06 上海交通大学医学院附属瑞金医院 一种斑马鱼nk/tcl肿瘤模型的构建方法及其应用
NL2037024B1 (en) * 2024-02-14 2025-08-22 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Janus kinase (JAK) inhibitors for treating cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001052892A2 (en) * 2000-01-24 2001-07-26 Genzyme Corporation Jak/stat pathway inhibitors and the uses thereof
AU2007207516A1 (en) * 2006-01-20 2007-07-26 Oregon Health And Science University Mutant JAK3 kinase in human leukemia

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6016042879; Ｌｅｕｃｈｅｍｉａ， ２００９， ２３（９）， ｐｐ．１６６７-１６７８ *
JPN6016042881; Ｉｎｔ． Ｊ． Ｌａｂ． Ｈｅｍａｔｏｌ．， ２０１０， ３２（４）， ｐｐ．４１９-４２６ *
JPN6016042883; Ｂｌｏｏｄ， ２００９， １１３（１２）， ｐｐ．２７４６-２７５４ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020536111A (ja) * 2017-10-06 2020-12-10 シンガポール ヘルス サービシーズ ピーティーイー リミテッド リンパ腫を処置する方法

Also Published As

Publication number Publication date
US20170029899A1 (en) 2017-02-02
SG10201605729TA (en) 2016-08-30
EP2782562B1 (en) 2016-12-21
CN104220051A (zh) 2014-12-17
WO2013077814A3 (en) 2013-10-10
EP2782562A2 (en) 2014-10-01
US20150292022A1 (en) 2015-10-15
CN104220051B (zh) 2017-04-19
US10378062B2 (en) 2019-08-13
WO2013077814A2 (en) 2013-05-30
SG11201402611WA (en) 2014-06-27

Similar Documents

Publication Publication Date Title
JP6630742B2 (ja) ファルネシルトランスフェラーゼ阻害剤を用いて癌患者を治療する方法
JP6103691B2 (ja) 真性赤血球増加症に関与するｊａｋ２の変異の識別方法
Sridaran et al. Inhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistance
US20160289663A1 (en) Novel chimeric gene atf7ip-pdgfrb of acute lymphoblastic leukemia
KR20080080525A (ko) 유전자 전사에 대한 ｆｇｆｒ３의 억제제의 효과
US10378062B2 (en) Natural-killer/T-cell lymphoma (NKTCL) susceptibility prediction, diagnosis and therapy
CN113337602A (zh) Mdm2抑制剂的治疗方法和生物标志物
TW202045158A (zh) Mdm2抑制劑的治療方法和生物標記物
de Martino et al. JAK3 in clear cell renal cell carcinoma: mutational screening and clinical implications
US20150322528A1 (en) Biomarkers associated with cdk inhibitors
Roider et al. The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial
WO2020150480A1 (en) Methods for treatment of lung cancers
JP2011500046A (ja) Ｅｔ−７４３治療のための予後分子マーカー
JP6858563B2 (ja) Ｂｒａｆ変異検出によるｅｇｆｒ阻害剤の効果予測
US20180221438A1 (en) Modulating uracil-dna glycosylase and uses thereof
EP2732287B1 (en) Methods of prognosing chronic lymphocytic leukemia
Zhang et al. GSTA1 conferred tolerance to osimertinib and provided strategies to overcome drug-tolerant persister in EGFR-mutant lung adenocarcinoma
CN109982705A (zh) 通过属于vav家族的原癌基因蛋白的磷酸化而被鉴定的肿瘤的治疗剂
Adam et al. The Multiple Potential Biomarkers for Predicting Immunotherapy Response—Finding the Needle in the Haystack. Cancers 2021, 13, 277
HK40061774A (en) Treatment methods and biomarkers for mdm2 inhibitors
Chow Regulation and Signaling Mechanisms of ROR1 in B cell Acute Lymphoblastic Leukemia
KR20230001587A (ko) 암의 예방 또는 치료용 약학 조성물
Hughes Overexpression of Adenylate Cyclase Isoforms Alters Cell Signaling Pathways in NF1-Null Malignant Peripheral Nerve Sheath Tumors
O’Brien ASH 2010 Orlando

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170428

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171003